Koufakis and colleagues pooled trial data in Advances in Therapy. In the SEMALEAN study, handgrip strength rose 4.5 kg at 12 months on semaglutide.
Recap by typeshit. Full story at BIOENGINEER.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
A viral video claimed GLP-1 drugs cause cancer and blindness. Researchers are still studying long-term safety, including the thyroid tumor warning.
An industry piece on the production challenges facing ADCs, bispecifics, peptides and other newer drug types, and how makers are solving them.
Loading…